Circulating growth arrest-specific protein 6 levels are associated with erythropoietin resistance in hemodialysis patients

Miao-Pei Chen¹, Chien-Wen Chen¹,², Jin-Shuen Chen³, Hung-Chung Mao¹,² and Chu-Lin Chou¹,³*

Abstract

Growth arrest-specific protein 6 (Gas6) works synergistically with erythropoietin (EPO) to increase the proliferation and maturation of erythroblasts. However, the role of Gas 6 levels on EPO resistance in hemodialysis (HD) patients remains unclear. Therefore, the objective of this study was the first to examine the correlation between plasma Gas6 levels and EPO resistance in HD patients. We enrolled 134 HD patients and 85 healthy individuals. The HD patients were divided into 2 groups: 98 non-EPO-resistant patients and 36 EPO-resistant patients. Plasma levels of Gas6, interleukin 6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), and albumin were quantified. Compared with non-EPO-resistant patients, EPO-resistant patients had elevated plasma concentrations of Gas6 (15.4 ± 3.3 vs. 13.7 ± 3.2 ng/mL, P = 0.006), IL-6 (3.1 ± 3.1 vs. 2.1 ± 1.5 pg/mL, P = 0.009), and hs-CRP (12.7 ± 25.2 vs. 4.5 ± 5.5 mg/L, P = 0.002). In EPO-resistant HD patients, plasma Gas6 levels were negatively correlated with albumin levels (r = −0.388, P < 0.021). Elevated Gas6 levels are associated with EPO resistance in HD patients. Also, EPO resistance is related to inflammation and malnutrition. Thus, circulating Gas6 levels could be used as the potential marker in HD patients with EPO resistance.

Keywords: Erythropoietin, Growth arrest-specific protein 6, Hemodialysis, High-sensitivity C-reactive protein, Interleukin 6

Background

Erythropoietin (EPO) resistance is one of the most common complications in anemia patients undergoing hemodialysis (HD). Most factors causing EPO resistance are associated with malnutrition, chronic inflammation, hyperparathyroidism, and inadequate dialysis in HD patients, which shorten the lifespan of erythrocytes (Macdougall and Cooper 2002; Kanbay et al. 2010). EPO resistance is a potential risk factor for mortality, cardiovascular disease, and stroke, which are associated with the high-dose use of EPO-stimulating agents and inability to achieve a target hemoglobin level (Kilpatrick et al. 2008; Szczech et al. 2008). Thus, a careful evaluation of EPO resistance is crucial in patient care for improving clinical outcomes.

Growth arrest-specific protein 6 (Gas6), a vitamin K-dependent protein, plays a role in cell growth, cell proliferation, anti-inflammation, and phagocytosis (Tjwa et al. 2008; Ekman et al. 2010a, b). Gas6 is expressed in some cell types, such as endothelial, smooth muscle, and bone marrow cells (Tjwa et al. 2008). It was recently reported that elevated circulating Gas6 levels are correlated with disease activity such as systemic inflammation (Ekman et al. 2010a, b), acute coronary syndrome (Jiang et al. 2009), acute pancreatitis (Uehara et al. 2009), and systemic lupus erythematosus (Ekman et al. 2011). In chronic kidney disease patients, Gas6 levels were associated with renal disease and inversely related to renal function, suggesting that Gas6 levels may serve as a biomarker for disease stage (Lee et al. 2012). In patients with critical limb ischemia, circulating Gas6 levels correlated with survival outcomes, indicating that Gas6 can be considered as a potential biomarker in clinical practice (Ekman et al. 2010a, b).
In anemic mice, Gas6, released by erythroblasts, enhanced and synergized with EPO receptor signaling to facilitate hemoglobin synthesis (Angelillo-Scherrer et al. 2008). However, to date, the correlation between Gas6 and EPO resistance remains unclear in HD patients. Therefore, the objective of this study was the first to investigate the correlation between circulating Gas6 levels and EPO resistance in HD patients.

Methods

Subjects

Healthy control and HD subjects were enrolled in this study at the Ping-Tung Christian Hospital. This study was approved by the human research ethics committee of the hospital (Approved No.: IRB171A), and informed consent was obtained from each patient. Between December 2009 and December 2010, 85 healthy subjects were randomly recruited from an unselected population, as the control group. The experimental group included 134 HD patients. Patients with sepsis, iron deficiency, folate deficiency, vitamin B deficiency, bone marrow diseases, and hematopoietic diseases were excluded from this study. The HD patients were further divided into two groups: EPO-resistant patients were defined as those receiving a high dose of EPO ≥ 40,000 U/month for a minimum of 6 months and with hematocrit (Hct) levels <33 %, and non-EPO-resistant patients were defined as those receiving a low dose of EPO < 40,000 U/month for a minimum of 6 months and with Hct levels >33 %. All patients underwent polysulfone HD 3 times/week (dialysis flow of 500 mL/min for 4 h, endotoxin <0.03 EU/mL). After enrollment, fasting morning serum samples were obtained from the subjects and were stored at −80 °C until analysis.

Biochemical assessments were performed, including measurement of Gas6, interleukin 6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), blood urea nitrogen (BUN), albumin, phosphate, and calcium levels were measured with standard methods using UniCel Dxc 800 (Beckman Coulter Inc., USA). Ferritin and i-PTH levels were measured using standard commercial assays (Cobas e411, Roche Diagnostics, USA). Hct levels were measured using standard commercial kits (Sysmex XE-5000, Sysmex Corporation, Japan). TIBC (µmol/L) was calculated as plasma transferrin concentration (g/L) × 1.4, and TSAT was calculated as the ratio of SI to TIBC (SI/TIBC). Urea clearance was expressed as Kt/V (K, dialyzer urea clearance; t, dialysis time; V, body urea volume), which is the measurement of dialysis adequacy. Kt/V values, calculated by Kt/V = Ln (Co/Ct) (Ln, natural logarithm; Co, postdialysis BUN; Ct, predialysis BUN), expressed the changes in plasma BUN levels before and after HD. To evaluate RBC osmotic fragility, 10 concentrations of NaCl, ranging from 0 to 0.9 %, were incubated with 50 µL of RBCs. The absorbance of the supernatant versus water was determined at 575 nm by using a spectrometer (μQuant, BioTek Instruments, Inc.). The NaCl concentration at which 50 % of the RBCs were lysed was considered as the median osmotic fragility (Wu et al. 1998).

Statistical analysis

Data are expressed as mean ± standard deviation. All statistical analyses were performed using Statistical Package for Social Science (SPSS for Windows, version 19.0; SPSS Inc., Chicago, IL). Statistical differences in variables were compared using the unpaired t test. Pearson correlation analysis was used to evaluate the bivariate relationship between individual variables and plasma Gas6 levels. A value of P ≤ 0.05 was considered statistically significant.

Results

Patient characteristics

The 85 control subjects comprised 33 healthy male and 52 healthy female subjects with an average age of 60.8 ± 10.8 years, and the 134 HD patients comprised 46 male and 88 female patients with an average age of 62.2 ± 13.5 years and an average HD period of 81.0 ± 39.9 months. The HD patients were further divided into 2 groups: (1) 36 EPO-resistant HD patients comprising 11 male and 25 female patients receiving a high dose of EPO ≥ 40,000 U/month for a minimum
of 6 months and with Hct levels <33%; and (2) 98 non-EPO-resistant HD patients comprising 35 male and 63 female patients receiving a low dose of EPO < 40,000 U/month for a minimum of 6 months and with Hct levels >33%.

Biochemical characteristics between normal and hemodialysis subjects
The clinical characteristics of the enrolled subjects are shown in Table 1. Compared with healthy subjects, HD patients had significantly higher concentrations of serum ferritin (453.9 ± 25.5 vs. 165.4 ± 110.0 ng/mL, \( P < 0.001 \)), i-PTH (445.7 ± 502.8 vs. 26.4 ± 12.9 pg/mL, \( P < 0.001 \)), phosphate (5.39 ± 1.48 vs. 3.59 ± 0.42 mg/dL, \( P < 0.001 \)), plasma Gas6 (14.16 ± 3.28 vs. 6.65 ± 1.75 ng/mL, \( P < 0.001 \)), IL-6 (2.35 ± 2.05 vs. 1.15 ± 1.89 pg/mL, \( P < 0.001 \)), and hs-CRP (6.7 ± 14.0 vs. 0.9 ± 0.9 mg/L, \( P = 0.002 \)). In contrast, compared with healthy subjects, HD patients had significantly lower levels of SI (61.2 ± 23.0 vs. 91.3 ± 36.6 μg/dL, \( P < 0.001 \)), TIBC (252.6 ± 59.1 vs. 335.4 ± 62.9 μg/dL, \( P < 0.001 \)), TSAT (25.4 ± 10.9 vs. 29.5 ± 17.3%, \( P = 0.031 \)), Hct (32.9 ± 2.5 vs. 40.0 ± 3.9%, \( P < 0.001 \)), and albumin (3.97 ± 0.36 vs. 4.56 ± 0.27 g/dL, \( P < 0.001 \)).

Elevated growth arrest-specific protein 6 and inflammation levels in erythropoietin-resistant hemodialysis patients
A comparison of blood biochemistry data between the EPO-resistant and non-EPO-resistant HD patients is presented in Table 2. Compared with non-EPO-resistant patients, EPO-resistant patients had elevated concentrations of plasma Gas6 (15.4 ± 3.3 vs. 13.7 ± 3.2 ng/mL, \( P = 0.006 \)), IL-6 (3.1 ± 3.1 vs. 2.1 ± 1.5 pg/mL, \( P = 0.009 \)), and hs-CRP (12.7 ± 25.2 vs. 4.5 ± 5.5 mg/L, \( P = 0.002 \)). However, non-EPO-resistant patients had higher Hct concentrations than EPO-resistant patients.

Negative correlation between growth arrest-specific protein 6 and albumin levels in erythropoietin-resistant hemodialysis patients
A comparison of clinical variables associated with Gas6 levels is presented in Table 3. In EPO-resistant HD patients, plasma Gas6 levels were negatively correlated with albumin levels \( (r = -0.388, P < 0.021) \). Moreover, in healthy controls, Gas6 levels were positively correlated with IL-6 levels but negatively correlated with Hct and albumin levels.

Discussion and conclusions
Our study is the first to demonstrate that EPO-resistant HD patients have higher Gas6 levels than non-EPO-resistant HD patients. Our results showed that elevated circulating Gas6 levels were associated with EPO resistance in HD patients. In addition to Gas6 levels, concentrations of inflammation markers, such as IL-6 and hs-CRP, were increased in EPO-resistant HD patients. Further analyses showed that circulating Gas6 levels

Table 2 A comparison of blood biochemistry data between the EPO-resistant and non-EPO-resistant HD patients

| Item                | Non-EPO resistance | EPO resistance | \( P \) value |
|---------------------|--------------------|----------------|--------------|
| N                   | 98                 | 36             |              |
| Ferritin (ng/mL)    | 445.4 ± 330.8      | 472.9 ± 310.0  | 0.668        |
| SI (μg/dl)          | 62.6 ± 22.3        | 578 ± 24.8     | 0.293        |
| TSAT (%)            | 25.6 ± 11.2        | 24.5 ± 10.0    | 0.618        |
| TIBC (μg/dl)        | 257.7 ± 58.0       | 241.4 ± 64.0   | 0.167        |
| i-PTH (pg/ml)       | 417.7 ± 460.0      | 5140 ± 6090    | 0.331        |
| Hematocrit (%)      | 33.5 ± 2.4         | 31.3 ± 2.7     | <0.001       |
| Albumin (g/dl)      | 40 ± 0.3           | 3.9 ± 0.4      | 0.173        |
| Phosphate (mg/dl)   | 5.3 ± 1.5          | 5.6 ± 1.5      | 0.233        |
| Calcium (mg/dl)     | 94 ± 0.8           | 92.0 ± 0.9     | 0.244        |
| Gas6 (ng/ml)        | 13.7 ± 3.2         | 15.4 ± 3.3     | 0.006        |
| IL-6 (pg/ml)        | 2.1 ± 1.5          | 3.1 ± 3.1      | 0.009        |
| hs-CRP (mg/l)       | 4.5 ± 5.5          | 12.7 ± 25.2    | 0.002        |
| Kt/V                | 1.79 ± 0.29        | 1.73 ± 0.32    | 0.272        |
| RBC fragility test (% of NaCl) | 0.413 ± 0.05 | 0.417 ± 0.04  | 0.700        |

Data are mean ± SD

Table 3 Clinical characteristics of study subjects

| Item              | Healthy control | Hemodialysis patient | \( P \) value |
|-------------------|-----------------|----------------------|--------------|
| N                 | 85              | 134                  |              |
| Ferritin (ng/mL)  | 165.4 ± 1100    | 453.9 ± 325.5        | <0.001       |
| SI (μg/dl)        | 91.3 ± 36.6     | 61.2 ± 23.0          | <0.001       |
| TSAT (%)          | 29.5 ± 17.3     | 25.4 ± 10.9          | 0.031        |
| TIBC (μg/dl)      | 335.4 ± 62.9    | 252.6 ± 59.1         | <0.001       |
| i-PTH (pg/ml)     | 26.4 ± 12.9     | 445.7 ± 502.8        | <0.001       |
| Hematocrit (%)    | 40.0 ± 3.9      | 32.9 ± 2.5           | <0.001       |
| Albumin (g/dl)    | 4.56 ± 0.27     | 3.97 ± 0.36          | <0.001       |
| Phosphate (mg/dl) | 3.59 ± 0.42     | 5.39 ± 1.48          | <0.001       |
| Calcium (mg/dl)   | 9.18 ± 0.37     | 9.33 ± 0.87          | 0.136        |
| Gas6 (ng/ml)      | 6.65 ± 1.75     | 14.16 ± 3.28         | <0.001       |
| IL-6 (pg/ml)      | 1.15 ± 1.89     | 2.35 ± 2.05          | <0.001       |
| hs-CRP (mg/l)     | 0.9 ± 0.9       | 6.7 ± 14.0           | 0.002        |
| RBC fragility test (% of NaCl) | 0.426 ± 0.034 | 0.414 ± 0.049 | 0.075        |

Data are mean ± SD

SI serum iron, TSAT transferring saturation, TIBC total iron-binding capacity, i-PTH intact parathyroid hormone, Gas6 growth arrest-specific 6, IL-6 Interleukin 6, Hs-CRP high sensitivity C-reactive protein, RBC red blood cell
were negatively correlated with albumin levels in EPO-resistant HD patients. Elevated circulating Gas6 levels may serve as a clinical marker for EPO resistance in HD patients.

In our study, circulating Gas6 levels were elevated in EPO-resistant HD patients. Our data are consistent with the results of recent studies. Studies show that circulating Gas6 levels are associated with disease activity, such as severe sepsis (Borgel et al. 2006) or septic shock (Gibot et al. 2007), acute coronary syndrome (Jiang et al. 2009), and glomerular injury in nephrotoxic nephritis (Yanagita et al. 2002). Moreover, elevated Gas6 levels were associated with increased mortality in patients with severe peripheral arterial disease, characterized by rest pain and gangrene in the legs (Ekman et al. 2010a, b). In chronic kidney disease patients, Gas6 levels increased with kidney disease stage progression and were inversely related to the estimated glomerular filtration rate \( (P < 0.0001) \). In mouse models, Gas6 enhanced EPO receptor signaling stimulating hemoglobin production, thus playing the role of a hemoglobin regulator (Angelillo-Scherrer et al. 2008). In our study, thus we observed that a clinical marker associated with EPO resistance in HD patients were linked to circulating Gas6 levels.

In addition to circulating Gas6 levels, plasma IL-6 and hs-CRP levels were significantly higher in EPO-resistant patients than in non-EPO-resistant patients. Some other studies have also reported elevated IL-6 and hs-CRP levels in EPO-resistant HD patients (Abe et al. 2011a, b; Shinzato et al. 2008). This indicates that EPO resistance is linked to systemic inflammation in HD patients. Recently, Gas6 was proposed to be a potential regulator of immune response in the development of systemic inflammation (Yanagita et al. 2002; Borgel et al. 2006; Hurtado and de Frutos 2010). In mouse models of inflammation, Gas6 induced the sequestration of circulating platelets and leukocytes on activated endothelium to form circulating leukocyte-platelet conjugates, resulting in thrombosis and inflammation (Tjwa et al. 2008). Moreover, it is known that inflammatory cytokines, such as hs-CRP, IL-6, and tumor necrosis factor-\( \alpha \), suppress erythropoiesis, resulting in inadequate response to recombinant human EPO treatment (Abe et al. 2011a, b; Shinzato et al. 2008; Goicoechea et al. 1998; Kalantar-Zadeh et al. 2004). In our study, Hct levels were significantly lower in EPO-resistant HD patients than in non-EPO-resistant HD patients (31.3 vs. 33.5 %, \( P < 0.001 \)).

Furthermore, plasma Gas6 levels were negatively correlated with serum albumin levels \( (r = -0.388, P < 0.021) \) in EPO-resistant HD patients, implying that EPO resistance could be linked to nutritional status. Recently, Lee et al. (2012) reported that higher Gas6 levels were associated with low albumin levels in chronic kidney disease patients, suggesting a possible connection between malnutrition and inflammation associated with worsening renal function. Moreover, resistance to EPO treatment was associated with low albumin levels in HD patients with depression (Afsar 2013). Furthermore, a lower response to EPO treatment was observed in diabetic HD patients with malnutrition-inflammation-atherosclerosis.

| Item            | Healthy control (\( N = 85 \)) | Non-EPO resistance (\( N = 98 \)) | EPO resistance (\( N = 36 \)) |
|-----------------|-------------------------------|----------------------------------|-------------------------------|
| Variable        | \( r \) | \( P \) value | \( r \) | \( P \) value | \( r \) | \( P \) value |
| Ferritin        | 0.022 | 0.845 | -0.140 | 0.167 | -0.206 | 0.236 |
| SI              | -0.192 | 0.078 | -0.060 | 0.558 | -0.148 | 0.395 |
| TSAT            | -0.117 | 0.287 | -0.09 | 0.373 | -0.154 | 0.378 |
| TIBC            | -0.018 | 0.871 | 0.067 | 0.508 | 0.068 | 0.699 |
| i-PTH           | 0.043 | 0.694 | 0.139 | 0.171 | 0.056 | 0.748 |
| Hematocrit      | -0.248 | 0.022 | 0.141 | 0.164 | -0.174 | 0.318 |
| Albumin         | -0.320 | 0.003 | -0.096 | 0.343 | -0.388 | 0.021 |
| Phosphatase     | 0.034 | 0.756 | -0.116 | 0.254 | -0.172 | 0.322 |
| Calcium         | -0.042 | 0.704 | -0.003 | 0.977 | 0.043 | 0.805 |
| IL-6            | 0.321 | 0.003 | -0.043 | 0.675 | 0.149 | 0.393 |
| hs-CRP          | 0.066 | 0.546 | -0.017 | 0.868 | 0.013 | 0.941 |
| Kt/V            | - | - | -0.065 | 0.524 | 0.300 | 0.081 |
| EPO dose        | - | - | -0.118 | 0.244 | -0.151 | 0.387 |

The correlations were estimated using the Pearson correlation test.

Gas6: growth arrest-specific 6, EPO: erythropoietin, SI: serum iron, TSAT: transferrin saturation, TIBC: total iron-binding capacity, i-PTH: intact parathyroid hormone, Hct: hematocrit, IL-6: Interleukin 6, Hs-CRP: high sensitivity C-reactive protein, EPO: erythropoietin.
syndrome (Abe et al. 2011a, b). Overall, EPO resistance is expected to be associated with nutritional and inflammation status (Bamgbola et al. 2009).

RBC fragility could be augmented by inadequate dialysis, which modifies cell membrane structure and shortens RBC lifespan (Stenvinkel and Barany 2002; Sotirakopoulou et al. 2004). In our study, RBC fragility levels and Kt/V values did not significantly differ between EPO-resistant and non-EPO-resistant HD patients, indicating adequate dialysis in both groups. Moreover, serum ferritin levels were adequate and did not significantly differ between the two groups. Sepsis, folate deficiency, vitamin B deficiency, bone marrow diseases, and hematopoietic diseases were not considered as factors causing EPO resistance in HD patients. The exclusion of these factors could have strengthened our study to demonstrate an association between circulating Gas6 levels and EPO resistance in HD patients.

In conclusion, ours is the first study to show elevated circulating Gas6 levels in EPO-resistant HD patients. Compared with non-EPO-resistant HD patients, EPO-resistant HD patients had significantly increased concentrations of plasma Gas6, IL-6, and hs-CRP. Moreover, circulating Gas6 levels were negatively correlated with albumin levels in EPO-resistant HD patients. Thus, EPO resistance in HD patients is associated with inflammation and nutritional status. Circulating Gas6 levels might be used as a potential biomarker for EPO resistance in HD patients. However, the cross-sectional design of our study was a limitation, and therefore, the relevance of these findings needs to be further investigated in longitudinal cohort studies.

Abbreviations
BUN: blood urea nitrogen; EPO: erythropoietin; Gas6: growth arrest-specific 6 (gas6) protein and genetic variations in the gas6 gene in patients with acute coronary syndrome. Am J Clin Pathol 131(5):738–743
Afsar B (2013) The relationship between depressive symptoms and erythropoietin resistance in stable hemodialysis patients with adequate iron stores. Int J Artif Organs 36(5):314–319
Kalantar-Zadeh K, Block G, McAllister CJ, Humphreys MH, Kopple JD (2004) Relationship between erythropoietin responsiveness, insulin resistance, and malnutrition-inflammation-atherosclerosis (mia) syndrome in hemodialysis patients with diabetes. Int J Artif Organs 34(1):16–25
Abe M, Okada K, Soma M (2013) Relationship between erythropoietin responsiveness, insulin resistance, and malnutrition-inflammation-atherosclerosis (mia) syndrome in hemodialysis patients with diabetes. J Am Soc Nephrol 24:2026–2034
Abe M, Okada K, Soma M, Matsumoto K (2011b) Relationship between insulin resistance and erythropoietin responsiveness in hemodialysis patients. Clin Nephrol 75(1):49–58
Afsar B (2013) The relationship between depressive symptoms and erythropoietin resistance in stable hemodialysis patients with adequate iron stores. Int J Artif Organs 36(5):314–319
Richter B, Scherer PR, Burnier M, Lambrechts D, Fish RJ, Tjwa M, Saisan S, Suganuma R, Delmot M, Martinez-Soria E, Maxwell PH, Lemke G, Goff SP, Matsushima GK, Eap HS, Chanson M, Collen D, Izu S, Schapira M, Conway EM, Carmeliet P (2008) Role of gas6 in erythropoiesis and anemia in mice. J Clin Invest 118(2):583–596
Bamgbola OF, Kaskell FJ, Coco M (2009) Analyses of age, gender and other risk factors of erythropoietin resistance in pediatric and adult dialysis cohorts. Pediatr Nephrol 24(3):571–579
Borgel D, Clauser S, Bornstain C, Bihe J, Bissery A, Remones V, Fagon JY, Aiach M, Diehl JL (2006) Elevated growth-arrest-specific protein 6 plasma levels in patients with severe sepsis. Crit Care Med 34(1):219–222
Ekman C, Lindner AK, Akeson P, Dahlback B (2010a) Plasma concentrations of gas6 (growth arrest-specific protein 6) and its soluble tyrosine kinase receptor saxl in sepsis and systemic inflammatory response syndromes. Crit Care 14(4):R158
Ekman C, Gottsater A, Lindblad B, Dahlback B (2010b) Plasma concentrations of gas6 and soluble ad correlate with disease and predict mortality in patients with critical limb ischemia. Clin Biochem 43(10–11):873–876
Ekman C, Jonsen A, Sturfelt G, Bengtsson AA, Dahlback B (2011) Plasma concentrations of gas6 and saxl correlate with disease activity in systemic lupus erythematosus. Rheumatology (Oxford) 50(6):1064–1069
Gibot S, Massin F, Cravoisy A, Dupays R, Barraud D, Nace L, Bollaert PE (2007) Growth arrest-specific protein 6 plasma concentrations during septic shock. Crit Care 11(1):R8
Goicoechea M, Martin J, de Sequera P, Quiroga JA, Ortiz A, Carreno V, Caramelo C (1998) Role of cytokines in the response to erythropoietin in hemodialysis patients. Kidney Int 54(4):1337–1343
Hurtado B, de Frutos PG (2010) Gas6 in systemic inflammatory diseases: with and without infection. Crit Care 14(5):1003
Jiang L, Liu CY, Yang QF, Wang P, Zhang W (2009) Plasma level of growth arrest-specific 6 (gas6) protein and genetic variations in the gas6 gene in patients with diabetes. Clin Chim Acta 390(1–2):82–88
Kalantar-Zadeh K, Block G, McAllister CJ, Humphreys MH, Kopple JD (2004) Appetite and inflammation, nutrition, anemia, and clinical outcome in hemodialysis patients. Am J Clin Nutr 80(2):299–307
Kanbay M, Perazella MA, Kasaoglu B, Karoglu M, Covic A (2010) Erythropoiesis stimulating agent-resistant anemia in dialysis patients: review of causes and management. Blood Purif 29(1):1–12
Kilpatrick RD, Critchlow CW, Fishbane S, Besarab A, Stehman-Breen C, Krishnan M, Bradbury BD (2008) Greater eotin alfa responsiveness is associated with...
with improved survival in hemodialysis patients. Clin J Am Soc Nephrol 3(4):1077–1083
Lee IJ, Hilliard B, Swami A, Madara JC, Rao S, Patel T, Gaughan JP, Lee J, Gadegbeku CA, Choi ET, Cohen PL (2012) Growth arrest-specific gene 6 (gas6) levels are elevated in patients with chronic renal failure. Nephrol Dial Transplant 27(11):4166–4172
Macdougall IC, Cooper AC (2002) Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. Nephrol Dial Transplant 17(Suppl 11):39–43
Schuett H, Luchtelfeld M, Grothusen C, Grote K, Schieffer B (2009) How much is too much? Interleukin-6 and its signalling in atherosclerosis. Thromb Haemost 102(2):215–222
Shinzato T, Abe K, Furusu A, Harada T, Shinzato K, Miyazaki M, Kohno S (2008) Serum pro-hepcidin level and iron homeostasis in Japanese dialysis patients with erythropoietin (epo)-resistant anemia. Med Sci Monit 14(9):CR431–CR437
Sotirakopoulos N, Tsitsios T, Stambolidou M, Athanasiou G, Peiou M, Kokkinou V, Mavromatidis K (2004) The red blood cell deformability in patients suffering from end stage renal failure on hemodialysis or continuous ambulatory peritoneal dialysis. Ren Fail 26(2):179–183
Stenvinkel P, Barany P (2002) Anaemia, rhuepo resistance, and cardiovascular disease in end-stage renal failure; links to inflammation and oxidative stress. Nephrol Dial Transpl 17(Suppl 5):32–37
Szczech LA, Barnhart HX, Inrig J, Reddan DN, Sapp S, Califf RM, Patel UD, Singh AK (2008) Secondary analysis of the choir trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 74(6):791–798
Tjwa M, Bellido-Martin L, Lin Y, Lutgens E, Plaisance S, Bono F, Delesquen-Touchard N, Herve C, Moura R, Billiau AD, Aparicio C, Levi M, Daemen M, Dewerchin M, Lupu F, Arnout J, Herbert JM, Wae M, Garcia de Frutos P, Dahlback B, Carmeliet P, Hoylaerts MF, Moons L (2008) Gas6 promotes inflammation by enhancing interactions between endothelial cells, platelets, and leukocytes. Blood 111(8):4096–4105
Uehara S, Handa H, Gotoh K, Tomita H, Sennshuu M (2009) Plasma concentrations of growth arrest-specific protein 6 and protein s in patients with acute pancreatitis. J Gastroenterol Hepatol 24(9):1567–1573
Wu SG, Jeng FR, Wei SY, Su CZ, Chung TC, Chang WJ, Chang HW (1998) Red blood cell osmotic fragility in chronically hemodialyzed patients. Nephron 78(1):28–32
Yanagita M, Ishimoto Y, Arai H, Nagai K, Ito T, Nakano T, Salant DJ, Fukatsu A, Doi T, Kita T (2002) Essential role of gas6 for glomerular injury in nephrotoxic nephritis. J Clin Invest 110(2):239–246